Global Research Management, Inc. — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$16,514	4
2023	Research	$671,240	24
2022	Research	$75,350	2
2021	Research	$56,750	4
2019	Research	$58,300	3

Breakdown

Who paid Research payments · program years 2019–2025

Alcon Research LLC $671,240 24 payments
Padagis US LLC $132,100 6 payments
Perrigo Company plc $58,300 3 payments
Oyster Point Pharma, Inc. $16,514 4 payments

Studies the money was for Research payments · program years 2019–2025

Long-term evaluation of safety and performance of Clareon Presbyopia-Correction IOLs PMCF Study of Clareon Vivity and Clareon PanOptix $663,990 13 payments
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimonidine Ophthalmic Suspension 1 percent to Simbrinza in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes $132,100 6 payments
Bioequivalence study between Perrigo's product and Azopt ophthalmic Suspension $58,300 3 payments
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) $16,514 4 payments
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512, a Cole Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-4) $4,479 7 payments
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $2,772 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.